Judit Sánchez, Marta Lesmes, Margarita Rubio, Beatriz Gal, Antonio S Tutor
Enhancing academic performance and student engagement in health education: insights from Work Station Learning Activities (WSLA)
BMC medical education
dengue human infection models dhims important tools downselect dengue vaccine candidates establish tetravalent efficacy advanced clinical field trials aimed provide data safety immunogenicity dhim evaluate dengue vaccine efficacy performed openlabel phase 1 trial university maryland baltimore md usa eligible participants healthy individuals aged 1850 years either previously received tetravalent dengue purified inactivated vaccine prime followed liveattenuated vaccine boost ie vaccinee group unvaccinated flavivirusnaive participants ie control group participants vaccinee group detectable prechallenge dengue virus1 neutralising antibody titres flavivirusnaive participants control group inoculated dengue virus1 strain 45az5 deltoid region 2765 months following booster dosing participants followedup days 416 following dengue virus1 live virus human challenge daily realtime quantitative pcr specific dengue virus1 rna detection dengue virus1 solicited local systemic adverse events recorded primary outcomes safety ie solicited local systemic adverse events vaccine efficacy ie dengue virus1 rnaaemia following dengue challenge study registered clinicaltrialsgov number nct04786457 january 2021 ten eligible participants enrolled six 60 vaccinee group four 40 control group daily quantitative pcr detected dengue virus1 rna nine 90 ten participants five 83 six vaccinee group four 100 control group mean onset rnaaemia occurred day 5 sd 10 vaccinee group versus day 8 15 control group 95 ci 1149 p0007 trend towards reduced rnaaemia duration vaccinee group compared control group 82 days vs 105 days 95 ci 008 468 p0056 mildtomoderate symptoms nine 90 ten leukopenia eight 89 nine elevated aminotransferases seven 78 nine commonly observed severe adverse events detected vaccinee group fever 389c three 50 six headache one 17 transient grade 4 aspartate aminotransferase elevation one 17 deaths reported participants tetravalent dengue purified inactivated vaccine prime liveattenuated vaccine boost unprotected dengue virus1 infection showed increased clinical immunological transcriptomic evidence inflammation potentially mediated preexisting infectionenhancing antibodies study highlights impact small cohort human challenge models studying dengue pathogenesis downstream vaccine development military infectious disease research program medical technology enterprise consortium advanced technology international